2016年WHO分类系统视角下的低级别胶质瘤手术治疗
这项双中心回顾性分析纳入1990至2016年间治疗的299例低级别胶质瘤患者,按2016年WHO分类重新分组。结果显示手术切除较活检显著改善中位总生存(p=0.001),全切除与更好生存相关(p=0.007);IDH野生型患者从放化疗联合中获益(p=0.02)。作者认为手术疗效在很大程度上取决于分子亚型。
要点
- 手术切除较活检显著改善低级别胶质瘤患者的中位总生存(p=0.001)。
- 全切除较部分切除或活检与更好生存相关(p=0.007),在IDH突变型和IDH野生型组中均如此。
- IDH野生型患者接受放化疗联合较单纯放疗或化疗有显著生存获益(p=0.02)。
核心结论
- 手术治疗对低级别胶质瘤结局的影响在很大程度上取决于肿瘤的分子亚型。
- 侵袭性更强的IDH野生型肿瘤患者似乎从更积极的治疗如全切除、多次切除和放化疗联合中获益。
研究设计与样本
- 双中心回顾性分析,纳入1990至2016年间治疗的299例低级别胶质瘤患者,所有肿瘤按2016年WHO分类重新分类。
- 分析基线及肿瘤特征、总生存、不同治疗方式和功能结局。
主要发现
- 112例(37.5%)为IDH突变且1p/19q共缺失,86例(28.8%)为IDH突变,101例(33.8%)为IDH野生型肿瘤。
- 各组中位总生存差异显著(p<0.001)。
- 226例患者接受手术切除,其中位总生存较活检组显著改善(p=0.001)。
- 全切除与更好生存相关(p=0.007),在全队列以及IDH突变组和IDH野生型组中均优于部分切除或活检。
- IDH野生型患者接受放化疗联合较单纯放疗或化疗有显著生存获益(p=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: According to the 2016 WHO classification lower-grade gliomas consist of three groups: IDH-mutated and 1p/19q co-deleted, IDH-mutated and IDH-wildtype tumors. The aim of this study was to evaluate the impact of surgical therapy for lower-grade gliomas with a particular focus on the molecular subgroups. METHODS: This is a bi-centric retrospective analysis including 299 patients, who underwent treatment for lower-grade glioma between 1990 and 2016. All tumors were re-classified according to the 2016 WHO classification. Data concerning baseline and tumor characteristics, overall survival, different treatment modalities and functional outcome were analyzed. RESULTS: A total of 112 (37.5%) patients with IDH-mutation and 1p/19q co-deletetion, 86 (28.8%) patients with IDH-mutation and 101 (33.8%) patients with IDH-wildtype tumors were identified. The median overall survival (mOS) differed significantly between the groups (p < 0.001). Surgical resection was performed in 226 patients and showed significantly improved mOS compared to the biopsy group (p = 0.001). Gross total resection (GTR) was associated with better survival (p = 0.007) in the whole cohort as well as in the IDH-mutated and IDH-wildtype groups compared to partial resection or biopsy. IDH-wildtype patients presented a significant survival benefit after combined radio-chemotherapy compared to radio- or chemotherapy alone (p = 0.02). Good clinical status (NANO) was associated with longer OS (p = 0.001). CONCLUSION: The impact of surgical treatment on the outcome of lower-grade gliomas depends to a great extent on the molecular subtype of the tumors. Patients with more aggressive tumors (IDH-wildtype) seem to profit from more intensive treatment like GTR, multiple resections and combined radio-/chemotherapy.
引用
- Delev D, Heiland DH, Franco P, et al. Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. J Neurooncol. 2018. PMID: 30467813. doi:10.1007/s11060-018-03030-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。